A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Rigel Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Immune Thrombocytopenic Purpura

Treatments: Drug: Placebo; Drug: Fostamatinib Disodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT02076412

2013-005453-76 (EudraCT Number)

C-935788-048

Details and patient eligibility

About

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of persistent/chronic ITP for at least 3 months
• Average platelet count< 30,000/µL (and none > 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts

Exclusion criteria

• Clinical diagnosis of autoimmune hemolytic anemia
• Uncontrolled or poorly controlled hypertension
• History of coagulopathy including prothrombotic conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

74 participants in 2 patient groups

Fostamatinib Disodium

Experimental group

Description:

Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.

Treatment:

Drug: Fostamatinib Disodium

Placebo

Other group

Description:

Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Treatment:

Drug: Placebo